TL;DR: The Centers for Medicare & Medicaid Services modified NCD 159 governing levocarnitine coverage for ESRD patients, with an effective date of March 7, 2026. Here's what billing teams need to know before submitting claims.
CMS levocarnitine coverage policy under NCD 159 Medicare sets strict clinical thresholds for intravenous levocarnitine in end-stage renal disease patients. The policy covers two specific indications — erythropoietin-resistant anemia and intradialytic hypotension — and excludes all other uses in the ESRD population. No specific CPT or HCPCS codes are listed in this version of the policy, but levocarnitine billing teams should verify code assignment through their Medicare Administrative Contractor.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS |
| Policy | Levocarnitine for use in the Treatment of Carnitine Deficiency in ESRD Patients |
| Policy Code | NCD 159 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | High |
| Specialties Affected | Nephrology, Dialysis Facilities, ESRD Billing Teams, RCM |
| Key Action | Audit active levocarnitine patients now — confirm plasma free carnitine levels, diagnosis documentation, and six-month response benchmarks are in the chart before March 7, 2026 |
CMS Levocarnitine Coverage Criteria and Medical Necessity Requirements 2026
CMS levocarnitine coverage policy under NCD 159 is narrow by design. Intravenous levocarnitine is only covered for ESRD patients who meet all of the following thresholds. If even one element is missing from the record, you're looking at a claim denial.
Minimum dialysis duration: The patient must have been on dialysis for at least three months before treatment starts. This is a hard floor — no exceptions documented in the policy.
Documented carnitine deficiency: The patient's plasma free carnitine level must be below 40 micromol/L. CMS specifies this must be measured by a "professionally accepted method as recognized in current literature." That's a documentation requirement, not just a clinical one. The measurement method matters for medical necessity support.
The patient must also show signs and symptoms of one of two covered indications — not just a low lab value alone. A plasma free carnitine level below 40 micromol/L is necessary but not sufficient. Levocarnitine billing hinges on that distinction. Pair the lab result with documented clinical presentation or the claim won't hold.
Covered Indication 1: Erythropoietin-Resistant Anemia
CMS defines this as a persistent hematocrit below 30% despite standard erythropoietin dosage with iron replacement. The treating team must also show they've investigated and adequately treated other potential causes. "Investigated and adequately treated" is doing real work in that sentence — vague documentation won't satisfy it.
This is not a coverage policy that rewards shortcuts. If your clinical team hasn't documented the erythropoietin dose, the iron replacement regimen, and the workup for alternative causes, the claim is vulnerable.
Covered Indication 2: Intradialytic Hypotension
This indication applies when hypotension during hemodialysis interferes with the intended dialysis delivery. Standard fluid management and other usual measures must have already been tried. The threshold is specific: hypotension must occur during at least two dialysis treatments in a 30-day period. Document those episodes by date, treatment session, and clinical response.
The Six-Month Review Requirement
CMS builds a mandatory reimbursement checkpoint into this policy. If the patient doesn't show documented improvement within six months of starting levocarnitine, coverage stops. Period.
This is a significant operational requirement for dialysis facilities and nephrology billing teams. You need a tracking mechanism — not a manual one. Six months from initiation, the chart must show objective improvement tied to the covered indication. If you can't show it, stop billing and document why treatment was discontinued.
Prior Authorization and MAC-Level Considerations
NCD 159 does not list a prior authorization requirement on its face. However, your Medicare Administrative Contractor may have supplemental local coverage determination rules or prior auth requirements layered on top of this national policy. Check with your MAC before assuming the NCD alone governs your claims.
If your patients cross state lines or your facility bills through multiple MACs, confirm each MAC's position on levocarnitine billing guidelines. National coverage determinations set the floor — MACs can add requirements, not remove them.
CMS Levocarnitine Exclusions and Non-Covered Indications
CMS draws a hard line here. All indications for levocarnitine other than the two listed above are non-covered in the ESRD population. That includes:
| # | Excluded Procedure |
|---|---|
| 1 | Oral levocarnitine (only intravenous is addressed by this policy) |
| 2 | Any indication not explicitly tied to erythropoietin-resistant anemia or intradialytic hypotension |
| 3 | Treatment initiated before the patient has completed three months on dialysis |
| 4 | Continued treatment when the patient shows no documented improvement within six months |
This is not a policy with gray zones for off-label clinical judgment. The language is explicit: "All other indications for levocarnitine are non-covered in the ESRD population." If your team has been billing for levocarnitine under any other rationale, that exposure starts the moment this modification takes effect on March 7, 2026.
Coverage Indications at a Glance
| Indication | Status | Criteria Summary | Notes |
|---|---|---|---|
| Erythropoietin-resistant anemia in ESRD | Covered | Hematocrit <30% with treatment; standard EPO + iron replacement failed; other causes investigated and treated; plasma free carnitine <40 micromol/L; on dialysis ≥3 months | Must document EPO dose, iron regimen, and workup for other causes |
| Intradialytic hypotension in ESRD | Covered | Hypotension interferes with dialysis delivery; standard fluid management tried; ≥2 episodes in 30 days; plasma free carnitine <40 micromol/L; on dialysis ≥3 months | Document episode dates and clinical response |
| Continued treatment (no improvement at 6 months) | Not Covered | Failure to demonstrate improvement within 6 months of initiation | Stop billing and document discontinuation |
| All other levocarnitine indications in ESRD | Not Covered | Any indication not listed above | Explicit exclusion — no exceptions stated |
| Levocarnitine in ESRD patients on dialysis <3 months | Not Covered | Minimum dialysis duration not met | Hard floor — no exceptions |
CMS Levocarnitine Billing Guidelines and Action Items 2026
The effective date of March 7, 2026 is close. These are the steps your billing and clinical teams need to take now.
| # | Action Item |
|---|---|
| 1 | Pull every active levocarnitine patient's chart today. Confirm the dialysis start date, the pre-treatment plasma free carnitine level, the covered indication, and the response documentation. If any of these elements are missing, the claim is at risk as of March 7, 2026. |
| 2 | Verify the six-month clock for every active patient. Calculate initiation dates and flag anyone approaching the six-month mark without documented improvement. If improvement isn't in the chart, get the clinical team to document it — or begin preparing for discontinuation. |
| 3 | Document the carnitine measurement method. CMS requires a "professionally accepted method as recognized in current literature." Your lab report alone may not be sufficient. The ordering provider should note the method used when documenting medical necessity. |
| 4 | Review your continued-treatment documentation pathway. For patients already on levocarnitine, CMS offers two routes to justify continued coverage: a documented pre-dialysis plasma free carnitine level below 40 micromol/L prior to treatment initiation, or a physician certification in the medical record stating that discontinuation would cause carnitine levels to drop below 40 micromol/L and result in recurrent anemia or hypotension. Make sure your physicians understand this — and are documenting it before claims go out. |
| 5 | Confirm your HCPCS code assignment with your MAC. This NCD 159 policy does not list specific billing codes. Contact your Medicare Administrative Contractor for the correct HCPCS code for intravenous levocarnitine administered in your dialysis setting. Billing with the wrong code against this coverage policy will produce a claim denial regardless of clinical eligibility. |
| 6 | Alert your clinical team to the "other causes" documentation requirement. For the erythropoietin-resistant anemia indication, CMS requires evidence that other causes were "investigated and adequately treated." Your physicians need to understand this is a billing requirement, not just a clinical one. If the chart doesn't show the workup, the claim won't survive a review. |
| 7 | Build a six-month tracking workflow. Manual tracking fails. Build a report or flag in your EHR that fires at the five-month mark for every active levocarnitine patient. That gives your team 30 days to gather improvement documentation or prepare for discontinuation. |
If you're not sure how this applies to your patient mix or dialysis billing setup, talk to your compliance officer before March 7, 2026. The documentation requirements here are specific enough that a chart audit before the effective date is worth the time.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Levocarnitine Under NCD 159
A Note on Codes
NCD 159 as modified does not list specific CPT, HCPCS, or ICD-10 codes in the policy document. This is common for older national coverage determinations that predate systematic code integration.
Contact your Medicare Administrative Contractor for the current HCPCS code applicable to intravenous levocarnitine in your billing context. Your MAC may also publish a companion local coverage determination with code-level guidance. Do not assume a code is appropriate without MAC confirmation — an incorrect code assignment will produce a claim denial even when clinical criteria are fully met.
For ICD-10 coding, work with your nephrology coders to ensure the diagnosis codes for ESRD, carnitine deficiency, erythropoietin-resistant anemia, and intradialytic hypotension are all represented accurately. Each covered indication maps to distinct diagnosis codes, and the primary diagnosis should reflect the indication being treated — not just the ESRD status.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.